Latest Response Genetics Inc. Stories
SAN FRANCISCO, July 31 /PRNewswire-USNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI) today announced the execution of a letter of intent (LOI) to collaborate with Response Genetics, Inc. (Nasdaq: RGDX) on molecular diagnostic testing and banking of advanced-stage Lung Cancer tissues. (Logo: http://www.newscom.com/cgi-bin/prnh/20090731/DC55399LOGO) Specific molecular features of tumors, including EGFR mutations, ras mutations, ERCC1, RRM1 or TS overexpression, have been...
- An evil spirit; a devil.
- A nightmare.